Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Levonorgestrel Clear all
Withdrawn Not applicable Interventional

Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period

NCT01088178
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)
Device
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
16 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and Safety Study of Vaginal Rings Containing Dapivirine and Levonorgestrel

NCT02855346
View directory record Official record
Conditions
HIV Prevention
Interventions
200 mg of DPV + 320 mg LNG, 200 mg of DPV
Combination Product
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

NCT03642210
View directory record Official record
Conditions
Menorrhagia
Interventions
Levonorgestrel 52 mg intrauterine system
Combination Product
Lead sponsor
Medicines360
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
29
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

NCT05505162
View directory record Official record
Conditions
Healthy Female Participants
Interventions
Zibotentan, EE/LNG
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 14, 2026, 1:52 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35

NCT00161226
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Levonorgestrel intrauterine system
Device
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Not applicable Interventional

Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women

NCT00096694
View directory record Official record
Conditions
HIV Infections
Interventions
Levonorgestrel-releasing intrauterine device (IUD)
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
8
States / cities
Los Angeles, California • Baltimore, Maryland • Fall River, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System

NCT07739589
View directory record Official record
Conditions
Residual Drug Amount of EE and LNG
Interventions
Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

NCT06783192
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, LNG/EE
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA

NCT02859337
View directory record Official record
Conditions
Obesity, Contraception
Interventions
UPA-ECx1, UPA-ECx2
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early vs. Interval Postpartum IUD Insertion

NCT03462758
View directory record Official record
Conditions
Contraception
Interventions
IUD
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
4
States / cities
La Jolla, California • San Diego, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 14, 2026, 1:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Weight Change Among Users of Three Progestin-Only Methods of Contraception Over a 12-Month Time Period

NCT01592058
View directory record Official record
Conditions
Weight Change
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
427 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 14, 2026, 1:52 AM EDT
Withdrawn Phase 3 Interventional

Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

NCT06904274
View directory record Official record
Conditions
Endometrial Hyperplasia
Interventions
BAY865028, Medroxyprogesterone acetate
Combination Product · Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • West Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

NCT00445887
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Laboratory Biomarker Analysis, Levonorgestrel, Placebo
Other · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
30 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
66
States / cities
Duarte, California • Los Angeles, California • Orange, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study

NCT01254292
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 29 Years · Female only
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
24
States / cities
Tucson, Arizona • La Mesa, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 14, 2026, 1:52 AM EDT
Active, not recruiting Phase 2 Interventional

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

NCT02397083
View directory record Official record
Conditions
Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions
Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System
Drug · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
18
States / cities
Greeley, Colorado • Loveland, Colorado • Honolulu, Hawaii + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

NCT03819114
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Levonorgestrel (LNG)
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Chicago, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2021 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

NCT06671405
View directory record Official record
Conditions
Dyslipidaemia
Interventions
AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

NCT01243580
View directory record Official record
Conditions
Healthy
Interventions
Ortho-Cyclen, AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 14, 2026, 1:52 AM EDT
Completed No phase listed Observational Results available

Same Day Oral EC and Implant Initiation

NCT04678817
View directory record Official record
Conditions
Contraception
Interventions
Etonogestrel contraceptive implant with oral levonorgestrel, Levonorgestrel intrauterine device, Copper T380A intrauterine device
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Salt Lake City, Utah • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 14, 2026, 1:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study

NCT02067663
View directory record Official record
Conditions
Contraception
Interventions
Paragard, Mirena
Device · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

NCT00551616
View directory record Official record
Conditions
Contraception
Interventions
CDB-2914, Levonorgestrel
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
16 Years and older · Female only
Enrollment
2,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
23
States / cities
Los Angeles, California • Santa Monica, California • Boulder, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen

NCT03324685
View directory record Official record
Conditions
Drug Interactions
Interventions
BIIB074, OC (ethinyl estradiol and levonorgestrel)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 14, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

US Cycle Control and Blood Pressure Study

NCT00920985
View directory record Official record
Conditions
Contraception
Interventions
Gestodene/EE (FC Patch Low, BAY86-5016), Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
346 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
28
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 14, 2026, 1:52 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

NCT07525791
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0662-0419, Oral contraceptive, Acetaminophen
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 14, 2026, 1:52 AM EDT